Cargando…
Tongmai Yangxin pill alleviates myocardial no-reflow by activating GPER to regulate HIF-1α signaling and downstream potassium channels
CONTEXT: The Tongmai Yangxin pill (TMYX) has potential clinical effects on no-reflow (NR); however, the effective substances and mechanisms remain unclear. OBJECTIVE: This study evaluates the cardioprotective effects and molecular mechanisms of TMYX against NR. MATERIALS AND METHODS: We used a myoca...
Autores principales: | Chen, Ting, Zhang, Yulong, Chen, Manyun, Yang, Pu, Wang, Yi, Zhang, Wei, Huang, Weihua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013430/ https://www.ncbi.nlm.nih.gov/pubmed/36896463 http://dx.doi.org/10.1080/13880209.2023.2184481 |
Ejemplares similares
-
Integrating Metabolomics and Network Pharmacology
to Explore the Mechanism of Tongmai Yangxin Pills in Ameliorating
Doxorubicin-Induced Cardiotoxicity
por: Shu, Lexin, et al.
Publicado: (2023) -
Development of a HPLC-MS/MS Method to Determine 11 Bioactive Compounds in Tongmai Yangxin Pill and Application to a Pharmacokinetic Study in Rats
por: Shen, Jiayuan, et al.
Publicado: (2018) -
Tongmai Yangxin Pill combined with metoprolol or metoprolol alone for the treatment of symptomatic premature ventricular complex: a multicenter, randomized, parallel-controlled clinical study
por: LIU, Li-Jun, et al.
Publicado: (2022) -
Mechanism of Yangxin Tongmai Decoction in the Treatment of Coronary Heart Disease with Blood Stasis Syndrome Based on Network Pharmacology and Molecular Docking
por: Zhang, Mengxue, et al.
Publicado: (2022) -
Tongmai Yangxin intervening in myocardial remodeling after PCI for coronary heart disease: study protocol for a double-blind, randomized controlled trial
por: Wang, Yongxia, et al.
Publicado: (2020)